Health Condition 1: A00-B99- Certain infectious and parasitic diseases Health Condition 2: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Health Condition 3: I00-I99- Diseases of the circulatory system Health Condition 4: K00-K95- Diseases of the digestive system Health Condition 5: N00-N99- Diseases of the genitourinary system Health Condition 6: G00-G99- Diseases of the nervous system Health Condition 7: J00-J99- Diseases of the res
Conditions
Interventions
Control Intervention1: Not applicable: Not applicable
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients in the age group > 1 month to 12 years who are newly admitted to the PICU and treated with either of analgesics, sedatives or neuromuscular blocking agents (either singly or in combination), will be included in the study. 2. Readmission of the same patient to PICU will be counted as a separate case enrolled. 3. Only the patients whose parents / legally acceptable representatives give written informed consent will be included.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1. Pre-existing Patients in the PICU. 2. Patients who die within 24 hours of PICU stay. These patients will be excluded as we wish to calculate the daily total dose of the drugs used which will not be possible when the patients die within 24 hours of PICU stay.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To determine the frequency of use of analgesics, sedatives and neuromuscular blocking agents in the PICU. 2.To study the modalities (intermittent boluses/continuous drip) and the route of delivery(intravenous/intramuscular/oral) of analgesics, sedativesand neuromuscular blocking agents in the PICU. 3.To determine underlying system affected and etiology(disease) for whichanalgesics, sedatives and neuromuscular blocking agents are used in the PICU. Timepoint: At Baseline and at discharge from the Pediatric ICU or at death in the Pediatric ICU | — |
Secondary
| Measure | Time frame |
|---|---|
| 4. To determine the indication for initiating analgesics, sedatives and neuromuscular blocking agents in the PICU. 5. To determine the duration of usageand maximum daily dose used for the analgesics, sedatives and neuromuscular blocking agents used in the PICU. 6. To determine the label/off-label use of the analgesics, sedatives and neuromuscular blocking agents in the PICU.Timepoint: At Baseline and at discharge from the Pediatric ICU or at death in the Pediatric ICU | — |
Countries
India
Contacts
Public ContactDr Prerana Modani
Seth GS Medical College and KEM Hospital
Outcome results
None listed